In this double-blind trial (n=78) depressed patients with suicidal ideation were administered either ketamine or the benzodiazepine, midazolam. Ketamine produced rapid improvement in suicidal ideation and mood in comparison to midazolam and had positive effects on measures of neurocognition. However, improvements in neurocognition were not correlated with changes in depression, suicidal thinking, or general mood.
Objective: Subanesthetic ketamine rapidly reduces depressive symptoms and suicidal ideation in some depressed patients. Its effects on neurocognitive functioning in such individuals with significant suicidal ideation is not well understood, even though certain neurocognitive deficits are associated with suicide behavior beyond clinical symptoms.
Methods: In this study, depressed patients with clinically significant suicidal ideation (n = 78) underwent neuropsychological testing before and 1 day after double-blind treatment with intravenous ketamine (n = 39) or midazolam (n = 39). A subgroup randomized to midazolam whose ideation did not remit after initial infusion received open ketamine and additional neurocognitive testing a day after this treatment. The primary outcome was change in performance on this neurocognitive battery. The study was conducted between November 2012 and January 2017.
Results: Blinded ketamine produced rapid improvement in suicidal ideation and mood in comparison to midazolam, as we had reported previously. Ketamine, relative to midazolam, was also associated with specific improvement in reaction time (Choice RT) and interference processing/cognitive control (computerized Stroop task)-the latter a measure that has been associated with past suicide attempt in depression. In midazolam nonremitters later treated with open ketamine and retested, reaction time and interference processing/cognitive control also improved relative to both of their prior assessments. Neurocognitive improvement, however, was not correlated with changes in depression, suicidal thinking, or general mood.
Conclusions: Overall, ketamine was found to have a positive therapeutic effect on neurocognition 1 day after treatment on at least 1 measure associated with suicidal behavior in the context of depression. Results suggest additional independent therapeutic effects for ketamine in the treatment of depressed patients at risk for suicidal behavior.
Authors: John G. Keilp, Sean P. Madden, Julia E. Marver, Abigail Frawley, Ainsley K. Burke, Mohammad M. Herzallah, Mark Gluck, J. John Mann & Michael F. Grunebaum
Ketamine is the most widely accessible and utilized psychedelic. The off-label use of ketamine for treating mental health disorders such as depression and anxiety has soared in recent years as a plethora of ketamine clinics have emerged across the globe. Although evidence-based research is accompanying this increase in use, we still have a lot to learn about how ketamine exerts its therapeutic effects and how it compares to conventional treatments.
In the present study, researchers compared the effects of ketamine in depressed patients with suicidal ideation to that of midazolam and explored the ensuing effects on neurocognitive function. Midazolam is a benzodiazepine that is commonly used as an anaesthetic. In this double-blind study, participants received intravenous ketamine (n=39) or midazolam (n=39).
- Ketamine produced rapid improvement in suicidal ideation and mood in comparison to midazolam.
- Ketamine was associated with improvements in specific reaction time and interference processing/cognitive control.
- Patients who had received midazolam but had not remitted were treated with ketamine at a later date. Similar neurocognitive effects seen in the original ketamine group were observed.
The findings of the present study suggest that ketamine has a positive on certain measures of neurocognition and reduces suicidal ideation in patients who are depressed. The onset of the effects elicited by ketamine was much more rapid and ultimately, more pronounced than that of midazolam. Such findings are important to advance our understanding of ketamine and are hugely beneficial to this particularly vulnerable patient group.
Find this paper
Journal of Clinical Psychiatry
November 2, 2021
Institutes associated with this publicationNew York State Psychiatric Institute
The New York State Psychiatric Institute (NYSPI), established in 1895, was one of the first institutions in the United States to integrate teaching, research and therapeutic approaches to the care of patients with mental illnesses.